Akebia Therapeutics, Inc. (AKBA) News
Follow Akebia Therapeutics, Inc. (AKBA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Akebia Therapeutics to Report Third-Quarter 2026 Results
Akebia Therapeutics says it will report third-quarter 2026 financial results and discuss recent business highlights.
EQUITY | Oct 29, 2026, 12:03 PM UTC
M
Akebia Therapeutics Q3'26 Earnings Preview: EPS Estimate at $(0.04)
Akebia Therapeutics is scheduled to report Q3'26 results on October 29; the release time is unspecified. EPS is estimated at $(0.04).
EQUITY | Oct 28, 2026, 11:05 AM UTC
L
Akebia Therapeutics Price Target Maintained With a $4.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 09:59 AM UTC
L
Akebia Therapeutics initiated at Buy by WestPark Capital
Akebia Therapeutics was initiated at Buy by WestPark Capital, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 03:48 PM UTC
L
Akebia grants inducement stock options under Nasdaq Rule 5635(c)(4)
Akebia Therapeutics granted one newly hired employee options to purchase an aggregate of 8,400 shares of its common stock under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
AKBA reports inducement grants under Nasdaq Rule 5635(c)(4)
Akebia Therapeutics reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
Akebia Therapeutics to hold investor meetings at 2026 Wells Fargo conference
Akebia Therapeutics announced CEO John P. Butler and CFO Erik Ostrowski will conduct investor meetings at the 2026 Wells Fargo Healthcare Conference in Boston.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
Akebia to hold investor meetings at 2026 Wells Fargo conference
Akebia Therapeutics plans investor meetings at the 2026 Wells Fargo Healthcare Conference in Boston.
EQUITY | Sep 01, 2026, 12:01 PM UTC
H
Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining over 100 points on Thursday. Shares of Western Digital Corp (NASDAQ: WDC ) fell sharply in pre-market trading following fourth-quarter results. Wes
EARNINGS | Aug 06, 2026, 12:04 PM UTC
L
Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Shares of SiTime Corp (NASDAQ: SITM ) rose sharply in pre-market trading after the company reported better-than-expected second- quarter financial results. SiTime reported quarterly earnings of $2.34 per share which beat
EARNINGS | Aug 06, 2026, 08:55 AM UTC
M
Akebia Initiates Phase 2 Trial For Ebribafusp
Akebia starts phase 2 trial for kidney disease treatment
EQUITY | Aug 03, 2026, 12:00 PM UTC
L
AKBA - Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
AKBA - Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
EARNINGS | Jul 29, 2026, 12:00 PM UTC
L
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ: AKBA ) with a Buy and maintains $6 price target.
EQUITY | Jul 01, 2026, 11:48 AM UTC
L
Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study Af
Akebia Therapeutics®, Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation’s largest privately held and faste
EQUITY | Jun 30, 2026, 12:09 PM UTC